Sep 19 2026 12:24 AM EST
Arrowhead Shares Slide as Interim Data and Institutional Sales Prompt Profit‑Taking
Arrowhead Pharmaceuticals (NASDAQ: ARWR) fell 8.93% on September 15 after the company released interim topline data on its first dual‑functional RNAi therapeutic and after a wave of insider sales, while the broader biotech sector was under pressure from rising rates.
The stock has dropped 18.1% over the past five trading days, extending a 7.0% decline earlier in the week that mirrored a sector‑wide sell‑off. Arrowhead reported second‑quarter FY2026 revenue of $73.7 million, well below the $542.7 million earned in the same quarter a year earlier, and a net loss of $132.7 million (‑$0.93 per diluted share). Cash and cash equivalents stand at $188.5 million with marketable securities of $1.595 billion, giving the company roughly $1.78 billion in total cash resources.
Interim Data on ARO‑DIMER‑PA
On September 15 the company announced interim topline results for ARO‑DIMER‑PA, a dual‑target RNAi candidate that knocks down PCSK9 and APOC3. The data showed mean maximal single‑dose reductions of 72 % for PCSK9 and 88 % for APOC3, with LDL‑C falling 54 %, triglycerides 73 %, non‑HDL cholesterol 61 % and ApoB 50 %. While the reductions are clinically meaningful, analysts noted that the magnitude fell short of consensus expectations for a first‑in‑class launch, prompting a reassessment of the near‑term commercial upside.
Financial Context and Recent Results
Revenue in Q2 FY2026 was $73.7 million, a 3.4% beat versus the consensus of $71.5 million but a 9.6% miss against a higher estimate of $81.59 million. R&D expense for the six‑month period rose to $350.5 million, reflecting continued investment in late‑stage programs such as SHASTA‑3/‑4, ARO‑MAPT and the dual‑functional candidate. The balance sheet shows total assets of $2.268 billion against liabilities of $1.669 billion, yielding a stockholders’ equity of $613.977 million. Debt stands at roughly $588.5 million (debt‑to‑equity ≈ 105%) with an interest‑coverage ratio of 5.9×.
Macro and Sector Factors
The sell‑off coincided with a Federal Open Market Committee meeting on September 14‑15 that signaled a possible rate hike, pushing the 10‑year Treasury yield above 5 %. Higher rates tend to depress valuation multiples for growth‑oriented biotech stocks. In addition, escalating Middle‑East tensions have lifted inflation expectations and strengthened the dollar, further pressuring risk‑off assets.
Pipeline and Strategic Partnerships
Arrowhead’s commercial engine remains its recently approved product REDEMPLO (plozasiran) for familial chylomicronemia syndrome, with approvals in the U.S., Canada, Australia, and China, and a pending European Commission decision. The company continues to receive significant upfront and milestone payments from partners: $300 million from Takeda, $175 million from Janssen, $40 million from Horizon Therapeutics, and a $25 million upfront from Madrigal for the ARO‑PNPLA3 program. Upcoming readouts include SHASTA‑3/‑4 (Q3 2026), ARO‑DIMER‑PA (late Q3 2026), and ARO‑MAPT (early Q4 2026).
Risks and Uncertainties
Key risks include the reliance on milestone‑driven revenue, which can be volatile if clinical timelines slip. Insider sales – notably the CEO’s 85,000‑share disposition in December 2025 and multiple director sales in August 2026 – may signal reduced confidence among insiders. The company also faces ongoing patent litigation with Ionis Pharmaceuticals, potential dilution from future convertible‑note conversions, and execution risk on late‑stage candidates such as ARO‑DIMER‑PA and ARO‑MAPT. Finally, broader market sentiment toward biotech stocks remains sensitive to interest‑rate movements and geopolitical uncertainty, which could exacerbate price volatility.